Kymera Therapeutics, Inc. (KYMR)
NASDAQ: KYMR · Real-Time Price · USD
115.43
-1.04 (-0.89%)
At close: Sep 9, 2026, 4:00 PM EDT
115.45
+0.02 (0.02%)
After-hours: Sep 9, 2026, 7:30 PM EDT
Kymera Therapeutics Revenue
Kymera Therapeutics had revenue of $65.00M in the quarter ending June 30, 2026, with 466.40% growth. This brings the company's revenue in the last twelve months to $105.00M, up 134.84% year-over-year. In the year 2025, Kymera Therapeutics had annual revenue of $39.21M, down -16.70%.
Revenue (ttm)
$105.00M
Revenue Growth
+134.84%
P/S Ratio
91.41
Revenue / Employee
$384,615
Employees
273
Market Cap
9.60B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 39.21M | -7.86M | -16.70% |
| Dec 31, 2024 | 47.07M | -31.52M | -40.11% |
| Dec 31, 2023 | 78.59M | 31.77M | 67.84% |
| Dec 31, 2022 | 46.83M | -26.01M | -35.71% |
| Dec 31, 2021 | 72.83M | 38.80M | 114.00% |
| Dec 31, 2020 | 34.03M | 31.10M | 1,059.99% |
| Dec 31, 2019 | 2.93M | - | - |
| Dec 31, 2018 | 2.93M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Bio-Techne | 1.22B |
| Ionis Pharmaceuticals | 874.09M |
| Axsome Therapeutics | 776.57M |
| Krystal Biotech | 440.48M |
| Protagonist Therapeutics | 281.99M |
| ImmunityBio | 165.79M |
| Cytokinetics | 67.67M |
| Praxis Precision Medicines | 7.46M |
KYMR News
- 16 hours ago - Kymera Therapeutics Transcript: Wells Fargo 21st Annual Healthcare Conference - Transcripts
- 7 days ago - Kymera Therapeutics to Participate in Upcoming September Investor Conferences - GlobeNewsWire
- 8 days ago - Kymera Therapeutics Announces Presentations on KT-621, a First-in-Class, Oral STAT6 Degrader, at the European Respiratory Society and European Academy of Dermatology & Venereology Congresses - GlobeNewsWire
- 9 days ago - Kymera Therapeutics price target raised to $170 from $135 at Guggenheim - TheFly
- 4 weeks ago - Kymera Therapeutics price target raised to $135 from $119 at Morgan Stanley - TheFly
- 4 weeks ago - Kymera Therapeutics price target raised to $135 from $120 at Citi - TheFly
- 4 weeks ago - Kymera Therapeutics price target raised to $139 from $133 at Barclays - TheFly
- 5 weeks ago - Kymera Therapeutics Earnings Call Transcript: Q2 2026 - Transcripts